Evidence map›Paper›PMID 36896122›Full record

ReviewInternational journal of nephrology2023

Critically Ill Patients with Renal Hyperfiltration: Optimizing Antibiotic Dose.

Jorge Rico-Fontalvo, José Correa-Guerrero, María Cristina Martínez-Ávila, Rodrigo Daza-Arnedo, Tomás Rodriguez-Yanez, Amilkar Almanza-Hurtado, José Cabrales, Carmen Julia Mendoza-Paternina, Alvaro Frías-Salazar, Julio Morales-Fernández

Open access · goldAbstract readReview
In one paragraph

Review in International journal of nephrology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Vancomycin loading dose and AUCPediatric research · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Jorge Rico-FontalvoColombian Association of Nephrology and Hypertension, Bogota, Colombia.
José Correa-GuerreroIntensive Care Unit Universidad de Cartagena, Cartagena, Colombia.
María Cristina Martínez-ÁvilaEpidemiology and Public Health, BIOTOXAM Group. Universidad de Cartagena, Cartagena, Colombia.ORCID https://orcid.org/0000-0002-1542-0249
Rodrigo Daza-ArnedoColombian Association of Nephrology and Hypertension, Bogota, Colombia.
Tomás Rodriguez-YanezIntensive Care Unit Universidad de Cartagena, Cartagena, Colombia.
Amilkar Almanza-HurtadoIntensive Care Unit Universidad de Cartagena, Cartagena, Colombia.
José CabralesDivision of Nephrology, Stanford Healthcare/Stanford University School of Medicine, Stanford, CA, USA.
Carmen Julia Mendoza-PaterninaDepartment of Medicine, Universidad del Sinu, Cartagena, Colombia.
Alvaro Frías-SalazarIntensive Care Unit Sanatorio Otamendi y Miroli Buenos Aires, Buenos Aires, Argentina.
Julio Morales-FernándezIntensive Care Unit Sanatorio Otamendi y Miroli Buenos Aires, Buenos Aires, Argentina.
University of Cartagena · COColombian Association of Surgery · COSanatorio Otamendi y Miroli · ARStanford University · USUniversidad del Sinú · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal hyperfiltration (RHF) is a prevalent phenomenon in critically ill patients characterized by augmented renal clearance (ARC) and increased of elimination of renally eliminated medications. Multiple risk factors had been described and potential mechanisms may contribute to the occurrence of this condition. RHF and ARC are associated with the risk of suboptimal exposure to antibiotics increasing the risk of treatment failure and unfavorable patient outcomes. The current review discusses the available evidence related to the RHF phenomenon, including definition, epidemiology, risk factors, pathophysiology, pharmacokinetic variability, and considerations for optimizing the dosage of antibiotics in critically ill patients.

Identifiers

PMID36896122
PMCPMC9991472
OpenAlexW4322627282

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.